Uterine cervical adenocarcinoma is rare, but its prevalence has increased. To improve outcomes and ensure the suitability of recent immunotherapies, the aim of this study was to evaluate the clinicopathological impact of the tumor immune microenvironment of uterine cervical adenocarcinoma. We investigated 148 adenocarcinoma cases, including 21 cases of adenocarcinoma in situ (AIS) and 127 cases of invasive adenocarcinoma, using immunohistochemistry to detect tumor-infiltrating 
| INTRODUCTION
Uterine cervical adenocarcinoma has become an important women's health issue because of its high prevalence and poor prognosis.
Adenocarcinoma accounts for approximately 10%-25% of uterine cervical cancer cases; 1,2 the remaining cases are due to squamous cell carcinoma (SCC). During the past two decades, the incidence of cervical adenocarcinoma has more than doubled, affecting mostly younger women. 1 Approximately 90% of cervical adenocarcinomas develop in relation to human papillomavirus (HPV) infection; however, some histological subtypes of cervical adenocarcinoma that are unassociated with HPV infection had worse prognosis than HPV-positive adenocarcinomas. 3 Although patients with adenocarcinoma are diagnosed at an early stage (stage I) and receive appropriate standard therapy, nearly 20% of patients die from the disease. 3 Therefore, more effective and opti- cytes and macrophages. 5 For example, programmed cell death 1 ligand-1 (PD-L1) expression on tumor cells has been reported to be associated with shorter survival in many cancer types and is one of the predictive markers for immunotherapy. 6 Furthermore, macrophage polarization has been considered a potential target of immunotherapy because it can promote tumor progression and therapeutic resistance. 7 The accumulation of evidence from many studies suggests that host antitumor immune reactions and tumor immune microenvironments differ according to the tumor histological type and tissue in which the cancer develops. [8] [9] [10] Regarding uterine cervical cancer, PD-L1 expression and a high ratio of FOXP3 + /CD3 + tumor-infiltrating lymphocytes (TILs) 11 were associated with poor prognosis. However, most of these cases were SCCs, and only a small number of adenocarcinomas were included in these studies. Therefore, we performed an evaluation of the tumor immune microenvironment in 148 uterine cervical adenocarcinomas and explored the association with prognosis and HPV infection status to elucidate the unique tumor microenvironment and potential immuno-therapeutic targets of uterine cervical adenocarcinoma. Immunohistochemistry was undertaken on formalin-fixed, paraffinembedded tissue sections as described previously. 14 We used 4-lmthick serial sections of representative blocks with antibodies (Table S2) . Immunohistochemistry without the primary antibody was carried out as a negative control.
| MATERIALS AND METHODS

| Study cohort
After immunohistochemistry, microscopic images were scanned and digitized using a NanoZoomer Digital Pathology system (Hamamatsu Photonics, Hamamatsu, Japan), and the density of the immune-labeled cells was analyzed using the image analysis software Tissue Studio (Definiens, Munich, Germany) ( Figure S1 ). 14 Numbers of TILs and tumor-associated macrophages (TAMs) were counted separately within tumor cell nests and the tumor stroma.
The density was calculated as the number of stained cells divided by the interested area. The PD-L1 expression on tumor cells was assessed manually and more than 5% of stained cells were positive. 15 The HPV infection status was surrogated by expression of p16
INK4a
, 16, 17 and evaluated based on histological subtypes. Human papillomavirus infection is evident by detection of HPV genes by PCR or in situ hybridization, although a systematic review of correlation between HPV infection and p16 overexpression indicated that p16 staining is better to predict the presence of HPV at the cut-off value of 70%. 18 Therefore, a case was considered HPV-positive when there were ≥70% tumor cells with p16 diffuse and strongly positive staining of nuclei and cytoplasm. [16] [17] [18] For survival and correlation analyses, patients were divided into two groups using the median as a cut-off.
| Statistical analysis
The non-parametric Wilcoxon signed-rank test was used to com- Among patients with invasive adenocarcinoma who were followed up for more than 5 years (n = 93), the disease-free survival (DFS)
rates were analyzed with the Kaplan-Meier method using the logrank test. The multivariate Cox proportional hazard regression model was used with the following covariates and stratified by adjuvant radiation therapy, TNM stage, lymph node metastasis, and age. Spearman's rank correlation analysis was applied to test for associations among the different types of infiltrating immune cells.
A P-value of < .05 was considered statistically significant. Statistical calculations were undertaken using SAS version 9.3 (SAS, Cary, NC, USA).
3 | RESULTS
| Destructive stromal invasion in relation to the density and type of TILs
Few TILs and TAMs were observed in non-cancerous cervical tissues without apparent inflammatory changes. In contrast, many cancer cases containing both AIS and invasive adenocarcinoma showed some host immune reaction representing TILs and TAMs (Table S3) .
To compare the immune microenvironments between non-invasive and invasive cancers appropriately, we evaluated tumor-infiltrating immune cells both within the tumor nest and in the adjacent tumor stroma separately ( Figure 1 , Table S3 
| DISCUSSION
Uterine cervical adenocarcinoma is rare but has an increasing prevalence and a poor prognosis. To improve the outcome and ensure the suitability of recent immunotherapies, we characterized the tumor immune microenvironment of cervical adenocarcinoma using the largest cohort so far. We revealed that a higher density of CD204 + M2
TAMs was significantly associated with shorter DFS (P = .049); no We still have very limited information regarding the immune microenvironment of cervical adenocarcinoma. 11, [19] [20] [21] Here, we showed that patients with tumors expressing PD-L1 tended to have favorable prognoses (Figure 1 ). Because of the low incidence of disease relapse, however, a statistically significant difference was not detected. Programmed cell death 1 ligand-1 has generally been reported to be a marker of attenuated antitumor immunity and poor prognosis. 6 Such paradoxical findings have been observed in other tumors, including breast cancer, lung cancer, Merkel cell carcinoma, 24, 25 and cervical SCC, 20 although these discordant results have not been explained clearly.
Expression of PD-L1 was less frequently observed in adenocarcinomas than in SCC (14% vs 54%), 19 and it was also observed in 95% of cervical SCCs, including non-invasive lesions, in another published study. 26 Heeren et al 19 There are some limitations to our study. We evaluated each subset of T cells by a single immunohistochemical staining, which could not determine detailed subsets of immune cells. Because of the low incidence of disease recurrence, we did not have enough statistical power to detect associations with prognosis using multivariate analysis, especially for the density of CD204 + macrophages, even though our study contains the largest number of cervical adenocarcinomas yet reported. Further multicenter studies are required to verify our findings.
In conclusion, tumor-infiltrating CD204 + M2 macrophages may be a predictor of poor prognosis in patients with cervical adenocarcinoma.
